Tagged with P

Poland Reinier Schlatmann, Philips CEO in Central and Eastern Europe, talks about the strategic significance of Poland for the company and how the implementation of Philips’ strategy and its focus on the health continuum can benefit the nation. Furthermore, he discusses the long history of Philips in Poland and how the…

Pharma In May 2018, PharmaBoardroom’s readers were asked what they felt were the biggest new sources of disruption to the traditional pharma industry today. Options included 3D Bioprinting, blockchain storage, genomics and artificial intelligence. 3D Bioprinting As Figure 1 (below) shows, 11 percent of our survey respondents felt that 3D bioprinting…

Spain Eva Prada, director of the British Chamber of Commerce in Spain, discusses trade relations between the UK and Spain and the activities of the Chamber in developing trust-based business relationships between companies and the government, their collaboration with key institutions such as ICEX, as well as their intention to work…

Spain Regina Múzquiz, director general of the Spanish Biosimilar Medicines Association (BioSim), discusses the importance of biosimilars as a tool to alleviate costs to the healthcare system and save EUR two billion in three years. Additionally, she points out the recent legal proposals on public procurement and reference pricing system that…

Malta Karl Sciberras, CEO of telecom projects, laboratory solutions and medical engineering specialist, Tektraco, discusses the company’s operations in Malta and Libya and why it is the partner of choice for clinics and hospitals.  Can you give our international readers an introduction to Tektraco?  “Our goal is to keep on improving…

Portugal Olga Insua, the new American general manager for Novo Nordisk Portugal, fresh off the plane from Spain, provides an exclusive insight into her impressive career at the company, the blending of business practices from Europe and New Jersey, and why patients should always be at the center of every process.…

Spain Jose Escribano, founder of Spanish biotech success story ALGENEX, discusses the company’s focus on using insects in its research, difficulties in accessing capital, and its future growth strategy. Can you please start by describing the opportunities that presented themselves, allowing you to create ALGENEX? “What we have done is to…

Portugal Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach when tackling market access hurdles. In suggesting improvements to the predictability of the pharmaceutical framework, Leão, soon to reach 30…

Portugal Salvador Fernandes, Ralph Steffen and Sofia Fernandes, chairman, production manager, and marketing manager respectively, discuss Sidefarma’s positioning in the Portuguese manufacturing landscape, and the strong relationship evolving between the government and the pharmaceutical industry. Furthermore, they highlight the importance of becoming successful in the domestic market before expanding internationally. Can…

Spain Jaume Pey, director general at the Spanish Association of Self-care (ANEFP), discusses the growth projections of the self-care segment in Spain, the impact that the ‘supresión del control previo sanitario’ (suppression of prior health control) has had on the advertising campaigns of ANEFP’s members, as well as the importance of…

Portugal Antonio Portela, seven years into leading the Bial operation in Portugal, shares his views on internationalization and how to maintain a stable company culture when approaching new and diverse markets. He discusses Portuguese market trends, future patent challenges and provides an intriguing insight into running a leading family-owned pharmaceutical company.…

Valeant Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson. Following the loss of nearly 93 percent of its value, the much maligned firm has announced that it will adopt…